Join
Live feed
·
PRReleasevia Quantisnow
Zai Lab Limited logo

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ZLAB· Zai Lab Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZLAB (Zai Lab Limited) and more on Quantisnow.